Advanced Cell Technology, Inc. (ACT), is amending the patient treatment protocol for the remainder of it Phase I clinical trials for Stargardt’s macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD) currently being conducted in the U.S. and will also submit an amendment in Europe for the SMD trial being conducted there, announced a company spokesperson. Patients with better vision, better than 20/100, will be eligible for enrollment in the remainder of the trials. By treating patients earlier in the course of the disease, ACT believes that the amended patient protocol will have a more significant impact on photoreceptor rescue and visual function. In previous protocols, only SMD patients with a visual acuity no better than hand movement in the treated eyes and dry AMD patients with a visual acuity of 20/400 were eligible. Read more.